Pfizer-BioNTech Covid-19 Vaccine Pharmaceutical Particulars

Medical Information
France
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you

This content is intended for French Healthcare Professionals. Would you like to proceed?

Due to the recent approval of the vaccine by the EMA and European Commission, the Summary of Product Characteristics for COMIRNATY available here, will be available soon on the French Public database of medications.



6.1 List of excipients

((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol
Potassium chloride
Potassium dihydrogen phosphate
Sodium chloride
Disodium phosphate dihydrate
Sucrose
Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. 

6.3 Shelf life

Unopened vial

Frozen vial
6 months at -90 °C to -60 °C
Within the 6 months shelf-life unopened vials may be stored and transported at -25 °C to -15 °C for a single period of up to 2 weeks and can be returned to -90 °C to -60 °C.

Thawed vial
1 month at 2 °C to 8 °C
Within the 1 month shelf-life at 2 °C to 8 °C, up to 12 hours may be used for transportation.
Prior to use, the unopened vaccine can be stored for up to 2 hours at temperatures up to 30 °C.

Once thawed, the vaccine should not be re-frozen.

Handling of temperature excursions once removed from the freezer
Stability data indicate that the unopened vial is stable for up to:

  • 24 hours when stored at temperatures from -3 °C to 2 °C
  • a total of 4 hours when stored at temperatures from 8 °C to 30 °C; this includes the 2 hours at up to 30 °C detailed above

This information is intended to guide healthcare professionals only in case of temporary temperature excursion.

Transfers of frozen vials stored at ultra-low temperature(< -60 °C)

  • Closed-lid vial trays containing 195 vials removed from ultra-low temperature frozen storage (< -60 °C) may be at temperatures up to 25 °C for up to 5 minutes.
  • Open-lid vial trays, or vial trays containing less than 195 vials, removed from ultra-low temperature frozen storage (< -60 °C) may be at temperatures up to 25 °C for up to 3 minutes.
  • After vial trays are returned to frozen storage following temperature exposure up to 25 °C, they must remain in frozen storage for at least 2 hours before they can be removed again.

Transfers of frozen vials stored at -25 °C to -15 °C

  • Closed-lid vial trays containing 195 vials removed from frozen storage (-25 °C to -15 °C) may be at temperatures up to 25 °C for up to 3 minutes.
  • Open-lid vial trays, or vial trays containing less than 195 vials, removed from frozen storage (-25 °C to -15 °C) may be at temperatures up to 25 °C for up to 1 minute.

Once a vial is removed from the vial tray, it should be thawed for use.

Diluted medicinal product

Chemical and physical in-use stability, including during transportation, has been demonstrated for 6 hours at 2 ºC to 30 ºC after dilution in sodium chloride 9 mg/mL (0.9%) solution for injection. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

6.4 Special precautions for storage

Store in a freezer at -90 °C to -60 °C.
Store in the original package in order to protect from light.
During storage, minimise exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.
Thawed vials can be handled in room light conditions.

For storage conditions after thawing and dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

2 mL clear multidose vial (type I glass) with a stopper (synthetic bromobutyl rubber) and a flip-off plastic cap with aluminium seal. Each vial contains 6 doses, see section 6.6.

Pack size: 195 vials

6.6 Special precautions for disposal and other handling

Handling instructions

Comirnaty should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

THAWING PRIOR TO DILUTION
  • The multidose vial is stored frozen and must be thawed prior to dilution. Frozen vials should be transferred to an environment of 2 °C to 8 °C to thaw; a 195 vial pack may take 3 hours to thaw. Alternatively, frozen vials may also be thawed for 30 minutes at temperatures up to 30 °C for immediate use.
  • The unopened vial can be stored for up to 1 month at 2 °C to 8 °C. Within the 1 month shelf-life at 2 °C to 8 °C, up to 12 hours may be used for transportation.
  • Allow the thawed vial to come to room temperature and gently invert it 10 times prior to dilution. Do not shake.
  • Prior to dilution, the thawed dispersion may contain white to off-white opaque amorphous particles.
DILUTION
  • The thawed vaccine must be diluted in its original vial with 1.8 mL sodium chloride 9 mg/mL (0.9%) solution for injection, using a 21 gauge or narrower needle and aseptic techniques.
  • Equalise vial pressure before removing the needle from the vial stopper by withdrawing 1.8 mL air into the empty diluent syringe.
  • Gently invert the diluted dispersion 10 times. Do not shake.
  • The diluted vaccine should present as an off-white dispersion with no particulates visible. Do not use the diluted vaccine if particulates or discolouration are present.
  • The diluted vials should be marked with the appropriate date and time.
  • After dilution store at 2 ºC to 30 ºC and use within 6 hours, including any transportation time. 
  • Do not freeze or shake the diluted dispersion. If refrigerated, allow the diluted dispersion to come to room temperature prior to use.
PREPARATION OF INDIVIDUAL 0.3 mL DOSES OF COMIRNATY
  • After dilution, the vial contains 2.25 mL from which 6 doses of 0.3 mL can be extracted.
  • Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab.
  • Withdraw 0.3 mL of Comirnaty.

    Low dead-volume syringes and/or needles should be used in order to extract 6 doses from a single vial. The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microlitres.

    If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial.
  • Each dose must contain 0.3 mL of vaccine.
  • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
  • Discard any unused vaccine within 6 hours after dilution.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.